









Clinical Immunology xxx (xxxx) xxx-xxx
Contents lists available at ScienceDirect
Clinical Immunology
journal homepage: www.elsevier.com
When neonatal inRammation does not mean infection: an early-onset mevalonate
kinase deQciency with interstitial lung disease
Carlo Pietrasanta ⁠a⁠, ⁠b, Francesca Minoia ⁠c, SoQa Torreggiani ⁠c, Andrea Ronchi ⁠a, Marco Gattorno ⁠d,
Stefano Volpi ⁠d⁠, ⁠e, Isabella Ceccherini ⁠f, Fabio Mosca ⁠a⁠, ⁠b, Giovanni Filocamo ⁠c, Lorenza Pugni ⁠a⁠, ⁠b⁠, ⁠
a Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, NICU, via della Commenda 12, 20122 Milan, Italy
b University of Milan, Department of Clinical Sciences and Community Health, via della Commenda 12, 20122 Milan, Italy
c Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Pediatria Media Intensità di Cura, via della Commenda 9, 20122 Milan, Italy
d Centro Malattie Autoin:ammatorie e Immunode:cienze, IRCCS Istituto Giannina Gaslini, via Gerolamo Gaslini 5, 16147 Genova, Italy
e DINOGMI, Università degli Studi di Genova, via Gerolamo Gaslini 5, 16147 Genova, Italy
f IRCCS Istituto Giannina Gaslini, UOC Genetica Medica, via Gerolamo Gaslini 5, 16147 Genova, Italy








A B S T R A C T
Systemic inRammation in neonates is attributable to an infection in almost all cases. When inRammation per-
sists, an autoinRammatory disease should be promptly suspected. We report here a case of mevalonate kinase
deQciency (MKD) that presented at birth with mild symptoms and signs suggestive for a perinatal infection, to-
gether with the uncommon Qnding of interstitial lung disease. An extensive diagnostic work-up, performed after
ineffective antibiotic treatment, demonstrated high levels of mevalonic acid in urine (7024mM/M of creatinine,
normal value <0.1). Next-generation sequencing showed a rare c.709A>T (p.T237S) homozygous mutation in
the MVK gene, consistent with MKD. Treatment with anakinra led to a prompt resolution of symptoms and a
sharp drop in serum inRammatory markers. The patient is now six months-old, currently undergoing evaluation
for hematopoietic stem-cell transplantation. To our knowledge, this is the Qrst case of MKD presenting within the
Qrst week of life with interstitial lung disease.
1. Introduction
Infections are the most common cause of inRammatory markers ele-
vation and/or fever in the neonatal period [1]. In the Qrst days of life,
a systemic inRammatory response may be also due to various non-in-
fectious conditions, such as perinatal asphyxia, meconium aspiration or
surgery [2]. However, systemic inRammation usually resolves after ad-
equate treatment during the acute phase of the disease [3].
Among causes of persistent inRammation, autoinRammatory dis-
eases (AIDs) deserve attention because of their possible devastating
consequences. AIDs are a group of rare diseases, characterized by the
presence of chronic or recurrent systemic inRammation, due to the
over-activation and dysregulation of immune response. Few of them can
present at birth, as in the case of cryopyrin-associated periodic syn-
dromes (CAPS), STING-associated vasculopathy with onset in infancy
(SAVI), and mevalonate kinase (MVK) deQciency (MKD) [4]. The di-
agnosis of AIDs requires a high degree of suspicion by neonatologists,
given their rarity but also the frequently deceptive, overlapping pheno-
types.
Here, we report an early-onset case of MKD, due to a rare homozy-
gous c.709A>T missense mutation (p.T237S) in the exon 8 of MVK
gene: this case was characterized by a previously unreported intersti-
tial lung disease, a feature overlapping with other AIDs, and a signif-
icant, prompt response to the interleukin-1 (IL-1) receptor antagonist
anakinra.
2. Case presentation
A female neonate born at 37weeks of gestational age (GA) was
transferred to our 3rd level neonatal intensive care unit (NICU) at
Abbreviations: AID, autoinRammatory disease; HIDS, hyper-IgD syndrome; MA, mevalonic aciduria; MVK, mevalonate kinase; MKD, mevalonate kinase deQciency; SAVI, STING-asso-
ciated vasculopathy with onset in infancy.
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16days of life (DOL) for persistent raised inRammatory markers in the
context of a suspected perinatal infection.
She was born by cesarean section, indicated for anomalies in uterine
arterial blood Row, with a birth weight of 2680g. Parents were of Mo-
roccan nationality, they were second cousins and had another daughter,
a healthy four-year-old girl. Maternal history was unremarkable, except
for a second pregnancy two years earlier interrupted by fetal death at
36weeks of GA. Vaccination status of the mother was unknown.
After birth, Apgar score was 10 at 1 and 5min of life and breast-
feeding was successfully started. On DOL 5, skin pallor and mild hypo-
tonia were noted, with no other clinical abnormality: blood tests and
cultures were requested for suspected sepsis. The white cell count was
14,09/mm⁠3 with 42% neutrophils, hemoglobin was 17g/dL, and C-re-
active protein (CRP) was 6.6mg/dL (normal value for age<1mg/dL).
Empiric antibiotic therapy (ampicillin plus gentamicin) was started, but
blood culture and surface swabs revealed no bacterial growth. Real-time
polymerase chain reaction (rt-PCR) for adenovirus, respiratory syncy-
tial virus and rhinovirus on nasopharyngeal swab was negative. Chest
X-ray revealed bilateral perihilar peribronchial thickening, with no con-
solidation, while abdominal and cardiac ultrasound were normal. Lum-
bar puncture was not performed. On DOL 9, CRP raised to 8.7mg/dL
and antibiotic therapy was switched to vancomycin plus ceftazidime for
presumed pulmonary infection. On DOL 15, CRP remained elevated and
the baby was transferred to our NICU.
At admission, the patient had normal vital signs, a mild tachypnea,
and the previously reported pallor. Hemoglobin was 9.2g/dL, biliru-
bin was 0.3mg/dL, blood arterial lactate, ammonium and glucose were
in the normal range. Antibiotic therapy with vancomycin plus cef-
tazidime was continued and clarithromycin was added waiting to rule
out a Chlamydia trachomatis infection. Blood, urine and cerebrospinal
Ruid (CSF) cultures were repeatedly negative for bacteria. A rt-PCR
was negative on both blood and CSF for herpes simplex virus 1 and 2,
varicella-zoster virus, human herpes virus 6, enterovirus, parechovirus,
cytomegalovirus and any bacterial pathogen. Serology for all viruses
listed above plus HIV and Treponema pallidum was negative. Electroen-
cephalography reported moderate diffuse anomalies of background ac-
tivity without major abnormalities or electrical seizures.
On DOL 20, the Qrst episode of temperature>38°C was recorded,
with a blood culture drawn during febrile peak still negative. Because
of worsening tachypnea and persistent abnormal chest X-ray (Fig. 1A),
a pulmonary computed tomography (CT) scan was performed. Imag-
ing revealed no congenital malformation but diffuse ground-glass bi-
lateral posterior inQltrates consistent with alveolar-interstitial lung dis-
ease (Fig. 1B). A retropharyngeal aspirate was negative for Pneumocystis
spp. DNA, and three gastric aspirates were negative for Mycobacterium
spp. DNA. Eighteen hours after CT scan, a palpable maculopapular skin
rash appeared on feet and hands, involving both dorsal and palmoplan-
tar surfaces (Fig. 1C-E). The rash vanished spontaneously 24h later. At
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that point any neonatal infection seemed unlikely, so antibiotics were
discontinued. A pediatric hematologist-oncologist was consulted and
diagnostic workup for familial haemophagocytic lymphohistiocytosis,
neonatal leukaemia and other malignancies was performed. Analysis of
bone marrow revealed normal tissue organization and cell morphology,
while levels of perforins, neuron-speciQc enolase and urinary catabo-
lites of catecholamines were also normal. A total body magnetic res-
onance imaging (MRI) revealed no abnormal mass or bone densities,
but showed a mild cerebellar hypoplasia and conQrmed the interstitial
lung disease. During the following ten days, systemic inRammation per-
sisted and worsened (Fig. 2A), with relapsing episodes of fever (Fig. 2B)
and skin rashes of varied appearance (Fig. 1F). The patient required
two transfusions of packed red cells for anemia, remained hypotonic
and failure to thrive became evident (Fig. 2B). A pediatric rheumatol-
ogist was involved in the management of the baby on DOL 24. Sys-
temic inRammation, skin rashes and interstitial lung disease were con-
sistent with a clinical suspicion of SAVI, thus the patient was tested for
type-I interferon (IFN) functional signature. In the meanwhile, consider-
ing the consanguinity of the parents and the high phenotypic variabil-
ity of AIDs, a next-generation sequencing (NGS) panel for 41 different
AID-related genes was requested, as well as urinary quantiQcation of
mevalonic acid and lysine. On DOL 36, type-I IFN signature came back
normal, but extremely high levels of mevalonic acid were found in the
urine (7024mM/M of creatinine, normal value < 0.1); lysinuria was
within normal levels. NGS conQrmed a homozygous c.709A>T mis-
sense mutation in the exon 8 of the MVK gene, coding for a protein sub-
stitution p.T237S, consistent with the diagnosis of MKD. Both parents
and the sister were found to be heterozygous carriers of the same muta-
tion.
On DOL 38, after obtaining parental informed consent, treatment
with the IL-1 receptor antagonist anakinra was started at the dose of
3.5mg/kg per dose once daily: the treatment was quickly effective on
systemic inRammation, leading to a regression of fever and skin rash,
a sharp drop in CRP from 14.4 to 1mg/dL, an increase in reticulo-
cytes within 48h and a significant weight gain during the following
days (Fig. 2A-B). Hypotonia significantly improved. The patient was dis-
charged from hospital on DOL 56 in good clinical conditions, with CRP
within the normal range, on anakinra therapy. Subsequent dose adjust
Fig. 2. Laboratory values (A), body temperature and body weight (B) before and after
treatment with anakinra.
ment of the drug, up to 4.5mg/Kg per day, was required to fully control
the clinical picture. She is now six months-old, still on anti-IL-1 treat-
ment without adverse events, and with satisfactory control of inRamma-
tory manifestations. Due to severe presentation of the disease and severe
enzymatic defect, she is currently undergoing a complete evaluation for
future hematopoietic stem cell transplantation (HSCT).
3. Discussion
We report here a neonatal-onset case of MKD due to a rare homozy-
gous mutation (p.T237S), mimicking a neonatal infection and with a
phenotype characterized by a previously unreported interstitial lung dis-
ease.
AIDs are a heterogeneous group of rare diseases caused by an altered
regulation of inRammatory responses [5]. Since the Qrst AID, familial
Mediterranean fever, was characterized at a molecular level back in
1997 [6], new syndromes and genetic mutations are continuously added
to the list of AIDs, and the knowledge of their pathogenetic mechanisms
is constantly increasing [7]. AIDs are monogenic diseases, but the in-
volved gene may harbor hundreds of mutations that frequently result in
a spectrum of clinical pictures rather than a single, pathognomonic phe-
notype. This is the case for MVK gene, located on chromosome 12q24
and encoding for MVK, an integral enzyme involved in cholesterol and
nonsterol isoprenoid biosynthesis.
Mutations in the MVK gene are responsible for MKD, with two pri-
mary manifestations: mevalonic aciduria (MA-OMIM 610377), the most
severe phenotype of MKD, and the hyper-IgD syndrome (HIDS-OMIM
260920) [8]. Clinical severity of MKD has been related to the residual
enzyme activity, with MA typically associated with less than 1%. Recur-
rent episodes of inRammation are the cornerstone of both conditions,
with fever, skin rash, diarrhea, vomiting and arthralgia/arthritis associ-
ated to increased acute phase reactants, leukocytosis and anemia. Ad-
ditional features of MA may include failure to thrive, severe neurologi-
cal impairment, dysmorphic features, cataracts, retinopathy, ataxia, he-
patosplenomegaly, and cholestasis. Furthermore, patients with overlap-
ping features, intermediate phenotype or unusual manifestations are not
uncommon [9].
MKD affects approximately 300 people worldwide, with 215 mu-
tations in the MVK gene described, 51 of which certainly pathogenic.
HIDS phenotype is ten times more common than MA [10 12]. MKD
with pure HIDS phenotype has an average age at diagnosis of 9.9years
[13], while in a case series of 114 European patients with both HIDS
and MA phenotype the median age at onset was 6months and the me-
dian age at diagnosis was 6.5years [11]. Of note, the diagnostic delay
has been dramatically reduced in the past 15years due to the increased
awareness of the disease and to the growing use of new technology in
genetic assays.
The diagnosis of MKD in neonates, as of most AIDs, is challenging
due to the rarity and unspeciQc symptoms that frequently recall those of
neonatal infections or of other neonatal diseases, such as malignancies.
In 2010, Lionetti et al. reviewed the AIDs that could act as a mimick-
ers of neonatal infections and highlighted the importance of an early
recognition, because most of them can have devastating permanent con-
sequences if left undiagnosed but, at the same time, may significantly
respond to non-speciQc (i.e. steroids) or targeted (i.e. biological treat-
ment) anti-inRammatory therapy [14].
The neonate here described, initially investigated and treated as a
probably infected newborn, was affected by MKD with some peculiar
characteristics, namely the very early disease onset, the rare causative
mutation, the previously unreported interstitial lung involvement, and
the good response to anti IL-1 treatment as an effective bridge treat-
ment to HSCT.
The T237S mutation of our patient has been recently classiQed as











C. Pietrasanta et al. Clinical Immunology xxx (xxxx) xxx-xxx
patients worldwide, 3 homozygous [15 17] and 1 compound heterozy-
gous [11]. In all of them, the described clinical features are consistent
with MA phenotype, due to an extremely low or absent residual activity
of MVK. The age at onset was known for 2 patients, one of which had
perinatal manifestations. Thus, this is the second known case of perina-
tal onset of MKD due to a homozygous p.T237S mutation. Furthermore,
to our knowledge, this is the Qrst case of MKD presenting within the Qrst
month of life with interstitial lung disease. Interestingly, a compound
heterozygous patient (T237S variant combined with I268T) reported by
ter Haar et al. [11] and also included in the case series by Papa et al.
[16], manifested recurrent episodes of pneumonia and died because of
acute respiratory distress syndrome. No interstitial lung involvement is
clearly reported, as well as no lung involvement at all is reported for
any of the homozygous patients.
In our case, the interstitial lung disease was conQrmed by two differ-
ent imaging studies, CT and MRI, performed between 20 and 35 DOL,
but was presumably already present in the Qrst chest X-ray performed at
DOL 5. Interstitial lung disease in neonates has an unclear prevalence,
being mainly caused by primary pulmonary anatomic or functional de-
fects, such as acinar dysplasia, bronchopulmonary dysplasia or muta-
tions affecting the synthesis of surfactant proteins [18]. Lung biopsy was
not performed in our patient because the diagnosis was made when she
was still in acceptable general conditions, and therapy was started be-
fore a possible worsening of respiratory function.
The association of early onset systemic inRammation, maculopapu-
lar skin rash and interstitial lung disease might be also suggestive for
SAVI [19]. All patients with SAVI reported by Liu et al. presented within
8weeks of life with systemic inRammation, 4/6 had skin rash at disease
onset and 5/6 had a conQrmed interstitial lung involvement, making
the suspicion of SAVI in our patient reasonable. Nonetheless, the nega-
tive signature testing for type-1 IFN-stimulated genes and the autosomal
dominant inheritance were not consistent with our case. SAVI was Q-
nally excluded with genetic testing. This case highlights how symptoms
may overlap also among different AIDs, especially at onset, and require
a full diagnostic workup including genetic testing for a deQnitive diag-
nosis.
As for the treatment, many AIDs have undergone a tremendous im-
provement in symptoms and prognosis over the past 15years with the
development of targeted (biological) therapies [20]. In MA-HIDS, bio-
logical treatment with inhibitors of the IL-1 signaling pathway can be
highly effective on systemic inRammation, leading to a prompt improve-
ment in clinical condition, with a crucial steroid-sparing effect [21].
However, anti-IL-1 therapy does not seem to significantly affect the neu-
rological symptoms, probably determined by the disruption in choles-
terol synthesis [22]. Three cases of allogeneic bone marrow transplanta-
tion and one of HSCT from cord blood stem cells have been reported so
far [23,24].
In summary, here we report a case of a neonatal-onset MKD char-
acterized by severe systemic inRammation and atypical interstitial lung
disease, initially mistaken for a perinatal infection. The uncommon pre-
sentation with interstitial lung disease tangled the differential diagnosis
also among AIDs, conQrming the frequent phenotypic overlap. Although
rare, neonatologists should be aware of AIDs, whose outcome can be
dramatically modiQed by an early diagnosis and adequate treatment. A
multidisciplinary approach involving a pediatric rheumatologist in the
management of unresolved neonatal systemic inRammation may speed
up the correct diagnosis of an early-onset AID and facilitate a prompt
start of the appropriate speciQc therapy.
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